

(19) **DANMARK**

(10) **DK/EP 2937358 T3**



Patent- og  
Varemærkestyrelsen

(12) Oversættelse af  
europæisk patentskrift

- 
- (51) Int.Cl.: **C 12 N 15/113 (2010.01)** **A 61 K 31/7088 (2006.01)** **C 07 H 21/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-01-02**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2018-09-19**
- (86) Europæisk ansøgning nr.: **15155831.9**
- (86) Europæisk indleveringsdag: **2009-06-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-10-28**
- (30) Prioritet: **2008-06-23 US 132973 P**
- (62) Stamansøgningsnr: **09798248.2**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **Antisense Therapeutics Ltd, 6 Wallace Avenue, Toorak VIC 3142, Australien**
- (72) Opfinder: **Klinger, Ety, 16 Baruch Agadati Street, 69930 Tzahala, Israel**  
**TESSLER, Shoshi, 24 Hanotrim Street, 30900 Zichron Yaaqov, Israel**  
**Hallak, Hussein, P.O. Box 19541, 9119401 Jerusalem, Israel**  
**TACHAS, George, 44 Sackville Street, Kew, Victoria 3101, Australien**  
**Diamond, Mark Paul, 3 Wallen Road, Hawthorn, Victoria 3122, Australien**
- (54) Benævnelse: **FREMGANGSMÅDER TIL BEHANDLING AF MULTIPEL SKLEROSE UNDER ANVENDELSE AF ANTISENSE-OLIGONUKLEOTIDER**
- (56) Fremdragne publikationer:  
**WO-A1-00/20635**  
**WO-A1-2006/086821**  
**GODFRAY J ET AL: "The use of nucleic acid tools for target validation in central nervous system therapy", DRUG DISCOVERY TODAY: TECHNOLOGIES, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 2, 1 October 2004 (2004-10-01) , pages 85-91, XP004767920, ISSN: 1740-6749, DOI: 10.1016/J.DDTEC.2004.06.003**  
**RAYBURN E R ET AL: "Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 13, no. 11-12, 1 June 2008 (2008-06-01), pages 513-521, XP022710733, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2008.03.014 [retrieved on 2008-05-03]**  
**DAVID R COREY: "RNA learns from antisense", NATURE CHEMICAL BIOLOGY, vol. 3, no. 1, 1 January 2007 (2007-01-01) , pages 8-11, XP055007854, ISSN: 1552-4450, DOI: 10.1038/nchembio0107-8**  
**TAFECH ALAEDDIN ET AL: "Destroying RNA as a therapeutic approach", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 13, no. 8, 8 April 2006 (2006-04-08), pages 863-881, XP002490060, ISSN: 0929-8673, DOI: 10.2174/092986706776361021**  
**COISNE CAROLINE ET AL: "Therapeutic targeting of leukocyte trafficking across the blood-brain barrier", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS, vol. 6, no. 4, 1 December 2007 (2007-12-01), pages 210-222, XP008156560, ISSN: 1871-5281**  
**MYERS K J ET AL: "Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical**

Fortsættes ...

symptoms in murine experimental autoimmune encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 160, no. 1-2, 1 March 2005 (2005-03-01), pages 12-24, XP027673277, ISSN: 0165-5728 [retrieved on 2005-03-01]

LIMMROTH VOLKER ET AL: "VLA-4 Antisense - An Oligonucleotide Targeting VLA-4 mRNA (ATL1102) Significantly Reduces New Active Lesions in Patients with RR-MS", NEUROLOGY; 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US; SEATTLE, WA, US, vol. 72, no. 11, Suppl. 3, 1 March 2009 (2009-03-01), page A112, XP008156239, ISSN: 0028-3878

# DESCRIPTION

[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 61/132,973 filed June 23, 2008.

[0002] Throughout this application various publications are referenced by Arabic numeral in parentheses. The full citation of the corresponding reference appears at the end of the specifications before the claims.

## Field and Background of the Invention

[0003] The present invention relates to methods of treating Multiple Sclerosis, particularly Relapsing forms of Multiple Sclerosis.

### Multiple Sclerosis

[0004] Multiple Sclerosis (MS) is a common neurological disease affecting more than 1 million people worldwide. Its prevalence rate varies between races and geographical latitude, ranging from more than 100 per 100,000 in Northern and Central Europe to 50 per 100,000 in Southern Europe. MS is the most common cause of neurological disability in young and middle-aged adults. Typically, the disease becomes evident before the age of 30 in about 50% of patients; in 25% of the patients the onset of disease is between the ages of 30 to 40, and in 25% the disease appears between the ages of 40 to 50. The female to male ratio is 2:1(4).

[0005] MS and the resulting neurological damage have a major physical, psychological, social and financial impact on the patients and on their families. The most common clinical symptoms of MS are paresis, paraesthesia, visual impairment, sexual, bowel, and urinary dysfunction, spasticity, and incoordination. 40 to 50% of patients suffer from cognitive dysfunctions. The extent of neurological deficit, the rate of progression, and the frequency of relapses are highly variable among the affected individuals (2-3).

[0006] Most MS patients have a normal life span marked by numerous years of severe progressive disability. The causes of death in patients with MS are respiratory or urinary tract infections rather than the disease itself. There are several distinct types of MS: relapsing-remitting multiple sclerosis (RRMS), which is characterized by unpredictable acute episodes of neurological dysfunction (relapses), followed by variable recovery and periods of clinical stability. 80% to 85% of MS patients are diagnosed with RRMS. More than 50% of the patients having RRMS develop sustained deterioration with or without relapses superimposed; this form is called Secondary Progressive MS (SPMS). Some MS patients developing a progressive deterioration from the beginning can also develop relapses later on; this uncommon form is

called primary progressive-relapsing multiple sclerosis (2-3).

**[0007]** Approximately 15% of overall MS patients develop a sustained deterioration of their neurological function from the beginning. This form is known as Primary Progressive MS or PPMS. The diagnosis is currently according to the McDonald's criteria (1). The outcome of a diagnostic evaluation is either "Multiple Sclerosis", "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS" (1). Finally, the term clinically isolated syndrome (CIS) applies to those patients who have suffered a first clinical attack but do not comply with the classical diagnostic criteria for definite MS. Nowadays, the presence of new lesions in a second MRI performed at least three months apart is an accepted criterion for a diagnosis of MS in these patients. 10%-20% of patients with an isolated syndrome will not develop MS.

**[0008]** MS is an inflammatory disease that damages the myelin in the Central Nervous System (CNS) causing neurological impairment and, frequently, severe disability. The etiology of MS remains mostly unknown. It is generally assumed that MS is triggered by a combination of autoimmunity, infection and genetic predisposition (2-3). Autoimmune response against myelin components proceeding through the activation of CD4+ T lymphocytes, loss of proper regulation on Th1/Th2 lymphocytes, production of anti-myelin antibodies by B lymphocytes, and possibly, inhibition of CD8+ cytotoxic/suppressor T lymphocytes underlie the pathogenesis of the MS.

**[0009]** MS is characterized by scattered regions of inflammation within the white substance of the CNS, brain and spinal cord. Focal inflammatory events eventually lead to demyelination of the axonal sheaths, degradation of nerve tissue, and finally, to irreversible neurological damage. Although the exact mechanism by which the MS process is initiated remains largely unknown, the target antigens of the autoimmune response in MS are believed to be part of the CNS myelin.

**[0010]** It is unclear whether the different courses of multiple sclerosis described are due to the same or to distinct pathophysiologic processes. Relapses are considered the clinical expression of acute inflammatory focal lesions whereas progression is considered to reflect the occurrence of demyelination, axonal loss and gliosis. Relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis are probably different stages of the same disease while primary progressive multiple sclerosis may imply different processes.

**[0011]** Myelin basic protein (MBP) and proteolipid protein (PLP) are the most common myelin components. Additional, less abundant constituents of myelin, such as myelin associated glycoproteins (MAG), myelin oligodendrocyte glycoproteins (MOG), and  $\alpha$ -B crystalline are also known. There is a considerable on-going debate regarding the true nature of the target antigen(s) in multiple sclerosis. In general, it appears that involvement of different antigens leads to certain differences in the courses of the disease (5-12).

#### **MRI-based multiple sclerosis diagnostic criteria**

**[0012]** All the diagnostic criteria for establishing the diagnosis of MS proposed in the last 50 years are based on three main principles: (1) demonstration of demyelinating lesions disseminated in space (DIS); (2) demonstration of demyelinating lesions disseminated in time (DIT); and (3) reasonable exclusion of alternative explanations for the clinical presentation (13).

### **Conventional MRI**

**[0013]** Conventional MRI techniques (cMRI), such as T2-weighted sequences and gadolinium-enhanced T1-weighted sequences, are highly sensitive for detecting MS plaques and can provide quantitative assessment of inflammatory activity and lesion load.

**[0014]** MRI studies in patients with Relapsing Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS), using gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) as a contrast agent, indicating blood-brain barrier disruption, have revealed that disease activity (defined as the presence of Gd-enhancing lesions on T1-weighted MRI) is 5 to 10 times more frequent than is apparent from clinical criteria alone (14).

### **Non-Conventional MRI**

**[0015]** Unenhanced T1-weighted imaging, measures of central nervous system atrophy, magnetization transfer imaging, proton magnetic resonance spectroscopy, diffusion-weighted imaging, and functional magnetic resonance imaging, provide a better approximation of the pathological substrate of the multiple sclerosis plaques, have increased the understanding of the pathogenesis of the disease, and have proven useful for studying the natural history of multiple sclerosis and monitoring the effects of new treatments (13).

### **Current Therapeutic Approaches**

**[0016]** The vast majority of treatments for multiple sclerosis have either immunosuppressive or immunomodulatory nature.

#### **Corticosteroids:**

**[0017]** Corticosteroids shorten the duration of a relapse but do not generally affect the degree of recovery. They have unspecific immunomodulatory and anti-inflammatory effects that decrease the blood-brain barrier (BBB) permeability, reduce edema, and improve axonal

conduction. Corticosteroids are often used to treat clinically significant relapses for a faster recovery. They have an acute anti-inflammatory activity which is short term and does not have an effect on the long term disease course.

**Interferon Beta:**

**[0018]** Two forms of recombinant interferon beta, beta-1a and beta-1b, have been approved for the treatment of patients with RRMS. The mechanism of their action in MS includes antiproliferative effects on T lymphocytes; decreased expression of major histocompatibility complex (MHC) class II antigens, and other immunoregulatory properties. The interferon-beta reduces the relapse rate in about 30% of patients with RRMS with mild to moderate disability. Major reduction in Gd-enhancing lesions on MRI scans could be demonstrated with interferon beta-1b, as well as reduction of EDSS progression. Interferon beta is administered as subcutaneous (s.c.) or intramuscular (i.m.) injection once or three times per week, depending on its type. It is associated with various adverse events, including flu-like symptoms, injection site reactions, serum aminotransferase elevation, and depression. Neutralizing antibodies have been reported in 5% to 40% of patients treated for three years and may lead to decreased efficacy.

**Glatiramer Acetate:**

**[0019]** Glatiramer acetate is a complex of synthetic peptides resembling myelin basic protein, which has shown a reduced annual rate of relapses of 30% in patients with RRMS. Glatiramer acetate is given daily by s.c. injection. The most common side effect is injection site reaction, which has been reported in up to 90% of patients. Another uncommon adverse event is a complex of immediate post injection reactions (IPIRs) which includes flushing, chest tightness, shortness of breath, palpitations, and anxiety.

**Natalizumab:**

**[0020]** Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule  $\alpha 4$ -integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. It is co-marketed by Biogen Idec and Élan as Tysabri, and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn's disease. Natalizumab was approved in 2004 by the United States Food and Drug Administration. It was subsequently

withdrawn from the market by its manufacturer after it was linked with three cases of the rare neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a, another immunosuppressive drug often used in the treatment of multiple sclerosis. After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program. In the European Union, it has been approved only for the treatment of multiple sclerosis.

### **Antisense Theory**

**[0021]** Antisense Oligonucleotides (AS-ONs) are short stretches of nucleotides or nucleotide derivatives that are complementary to a region of targeted RNA and can specifically suppress expression and other aspects such as processing of that particular transcript. The exact mechanism(s) of AS-ON action remains unclear, but is known to be different depending on the type of AS-ONs. Generally, these molecules block gene expression by hybridizing to the target mRNA, resulting in subsequent double-helix formation. This process can occur at any point such as transcription, initiation of translation, or during translation. Some of the possible mechanisms are disruption of splicing, impaired mRNA transport, disruption of translation of the transcripts as well as decreased stability of the mRNA transcript. In the case of many antisense oligodeoxyribonucleotides (AS-ODNs), cellular RNase H is able to bind to the DNA-RNA duplex and hydrolyze the RNA, resulting in reduced transcript numbers and decreased production of protein. Modifications to the deoxy moiety at the 2'-sugar position usually prohibits RNase H recruitment and action in that region of an AS-ODN (16).

**[0022]** Modified AS-ONs or AS-ON analogs are often employed for *in vivo* antisense applications due to their increased stability and nuclease resistance. A longer serum half-life ensures that the AS-ON has ample time to reach and interact with its target RNA in the tissue. AS-ODNs with phosphorothioate backbones are widely used due to their longer serum half-life and the fact that they are a suitable RNase H substrate. However, phosphorothioates display high affinity for various cellular proteins, which can result in sequence-nonspecific effects. Many AS-ONs with 2'-modifications of the sugar with groups such as O-methyl, fluoro, O-propyl, O-allyl, or many others exhibit greater duplex stability with their target mRNA and greater specificity but antisense effects in that 2' modified region are usually independent of RNase H. These modifications create bulk at the 2' position, causing steric hindrance to play a significant role in increasing nuclease resistance. Nucleotide analogs, such as peptide nucleic acids, generally are also nuclease-resistant and often demonstrate superior hybridization properties due to modified backbone charge, although they usually are not acceptable substrates for RNase H (16).

**[0023]** The traditional goal of the antisense approach to therapeutics is to decrease the level of key proteins in the disease pathogenesis. The use of antisense oligonucleotides as therapeutics has the potential advantage of much greater specificity compared to conventional small molecule drugs. The majority of drugs currently in use modulate the activity of specific proteins by either binding directly to the protein of interest or by binding to other proteins, such

as cell surface receptors, which then modulate the target protein. Due to the large number of related proteins, activity classes and protein families performing the same or very similar function, small molecule drugs often bind to, and affect the activity of, more than one target protein. In contrast, the effectiveness of AS-ONs relies on highly specific base-pairing between the oligonucleotide and the target RNA. Therefore, antisense technology enables targeting of a single member of a closely-related protein family and designing therapeutic agents displaying fewer non-specific toxic effects than other, less selective, agents (17-21).

#### **VLA-4 Integrin**

**[0024]** Integrins are heterodimeric adhesion molecules that play key roles in leukocyte activation, trafficking, and signaling. The VLA-4 integrin consists of  $\alpha 4$  chain non-covalently linked to the  $\beta 1$  subunit. It is expressed on most leukocytes, whether they occur in peripheral blood, lymphoid tissue, or at sites of inflammation in various organs.  $\alpha 4\beta 1$  binds to VCAM-1 on the activated endothelium and to the CS1 segment of fibronectin found in extracellular matrix. These interactions are critical for leukocyte migration across endothelium and into inflamed tissues. Ligand binding by  $\alpha 4$  integrins has diverse biological consequences. The best-known role for  $\alpha 4$  is its function as an adhesion molecule guiding leukocytes across vascular endothelium and into sites of inflammation. Leukocytes are recruited from the blood and into tissues by a multi-step process that involves an initial transient rolling of cells along the vascular endothelium followed by firm adhesion and subsequent trans-endothelial migration. The  $\alpha 4$  integrin is unique among adhesion molecules in that it can support both the rolling and firm adhesion steps (22).

**[0025]** Godfrey, J. et. Al., Drug Discovery Today, vol. 1, no. 2, 2004, 85-91 discusses the main challenges facing target validation today. The discussion focusses on the on-going genomics revolution which is generating an unprecedented number of potential targets. Existing technologies, such as mouse-knockouts, are struggling to provide the throughput now required. Nucleic acid tools including antisense, RNA interference, ribozymes and aptamers offer a potentially higher throughput means of manipulating gene expression and thus validating targets in complex biological systems such as the central nervous system.

**[0026]** Rayburn, E. R. et. Al., Drug Discover Today, vol. 13, no. 11-12, 2008, 513-521 discusses antisense oligonucleotides that can regulate gene expression in living cells. As such, they regulate cell function and division, and can modulate cellular responses to internal and external stresses and stimuli. Although encouraging results from preclinical and clinical studies have been obtained and significant progress has been made in developing these agents as drugs, they are not yet recognized as effective therapeutics. Several major hurdles remain to be overcome, including problems with efficacy, off-target effects, delivery and side effects. The lessons learned from antisense drug development can help in the development of other oligonucleotide-based therapeutics such as CpG oligonucleotides, RNAi and miRNA.

**[0027]** Corey, D. R., Nature Chemical biology, vol.3, no.1, 2007, 8-11 comments on RNA



interference which provides powerful tools for controlling gene expression in cultured cells. Whether RNAi will provide similarly powerful drugs is unknown. The authors comment that lessons from development of antisense oligonucleotides drugs may provide some clues.

**[0028]** Tafech, A. et. Al., *Current Medicinal Chemistry*, vol. 13, no. 8, 2006, 863-881 discusses the ability to target RNA, mRNA and viral RNA in particular, for degradation is a powerful approach in molecular biology and pharmacology. Such approaches can be used in the study of gene function as in functional genomics, in the identification of disease-associated genes, and for the treatment of human diseases. This review provides a comprehensive up-to-date look at all the current available technologies used for the destruction of RNA, with a focus on their therapeutic potential. This includes approaches that utilize the activity of protein ribonucleases such as antisense oligonucleotide, small interfering RNA, RNase P-associated external guide sequence, onconase and bovine seminal RNase. Sequence-specific approaches that do not utilize activity of protein ribonucleases, such as ribozyme and DNzyme, are also reviewed and discussed. This review provides a useful starting framework for researchers interested in using the RNA-destruction methodologies on the bench and in the clinic, and serves as a stimulus for further development of novel and more potent RNA degradation technologies.

**[0029]** Coisne, C. et. Al., *Inflammation and allergy drug targets*, vol. 6, no. 4, 2007, 210-222 discusses the central nervous system (CNS) which it suggests has long been regarded as an immune privileged organ implying that the immune system avoids the CNS not to disturb homeostasis, which is critical for proper function of the neurons. They suggest that it is accepted that immune cells do in fact gain access to the CNS and that immune responses are mounted within this tissue. However, they suggest that the unique CNS microenvironment strictly controls these immune reactions starting with tightly regulating immune cell entry to the tissue. The endothelial blood-brain barrier (BBB) and the epithelial blood cerebrospinal fluid (CSF) barrier control immune cell entry into the CNS which is rare under physiological conditions. During a variety of pathological conditions of the CNS such as viral or bacterial infections or during inflammatory diseases such as multiple sclerosis, they suggest that immunocompetent cells readily traverse the BBB and enter the CNS.

**[0030]** Myers, K. J. et. Al., *Journal of Neuroimmunology*, vol.160, no. 1-2. 2005, 12-24 discusses the use of an antisense oligonucleotide (ASO) specific for mRNA of the alpha chain (CD49d) of mouse VLA-4 to downregulate VLA-4 expression and alter central nervous system (CNS) inflammation. ISIS 17044 potently and specifically reduced CD49d mRNA and protein in cell lines and in ex-vivo-treated primary mouse T cells. When administered prophylactically or therapeutically, ISIS 17044 reduced the incidence and severity of paralytic symptoms in a model of experimental autoimmune encephalomyelitis (EAE). This was accompanied by a significant decrease in the number of VLA-4+ cells, CD4+ T cells, and macrophages present in spinal cord white matter of EAE mice. ISIS 17044 was found to accumulate in lymphoid tissue of mice, and oligonucleotide was also detected in endothelial cells and macrophage-like cells in the CNS, apparently due to disruption of the blood-brain barrier during EAE. They suggest that these results demonstrate the potential utility of systemically administered antisense

oligonucleotides for the treatment of central nervous system inflammation.

### Summary of the Invention

**[0031]** The invention provides pharmaceutical compositions for use in a method of treating multiple sclerosis as defined in the claims. The present disclosure also sets out ('provides') a number of other aspects and embodiments as discussed herein below which may facilitate understanding of the present invention, which is defined by the claims.

**[0032]** This disclosure provides a method for treating a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines ( $\text{MeC}$ ),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby treat the human subject.

**[0033]** This disclosure also provides a method for inhibiting the accumulation of new active brain lesions in a human subject afflicted with a form of multiple sclerosis detectable by MRI, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines ( $\text{MeC}$ ),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby inhibit the accumulation of new active brain lesions in the human subject detectable by MRI.

**[0034]** This disclosure additionally provides a method for inhibiting an increase in the volume of gadolinium-enhancing brain lesions of a human subject afflicted with a form of multiple sclerosis detectable by MRI, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines ( $\text{MeC}$ ),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby inhibit an increase in the volume of gadolinium-enhancing brain lesions detectable by MRI image.

**[0035]** This disclosure further provides a method for reducing level of VLA-4 in the blood of a human subject afflicted with a form of multiple sclerosis comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines ( $\text{MeC}$ ),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby reduce the level of VLA-4 in the blood of the human subject afflicted with the form of multiple sclerosis.

**[0036]** This disclosure also provides a method for inhibiting progression of disability in a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to a human subject afflicted with multiple sclerosis a pharmaceutical composition comprising a

pharmaceutically acceptable carrier and therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines (MeC),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby inhibit progression of disability in the human subject.

**[0037]** This disclosure furthermore provides a method for reducing the relapse rate in a human subject afflicted with a relapsing form of multiple sclerosis, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines (MeC) are 5-methylcytosines,

or a , pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby reduce the relapse rate in the human subject afflicted with the relapsing form of multiple sclerosis.

**[0038]** This disclosure provides a method for inhibiting the accumulation of new active brain lesions, decreasing or inhibiting an increase in the volume of gadolinium-enhancing brain lesions, and reducing the relapse rate in a human subject afflicted with a relapsing form of multiple sclerosis, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

1. a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;
2. b) the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;
3. c) the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;
4. d) the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and
5. e) all cytosines (<sup>Me</sup>C) are 5-methylcytosines,

or a pharmaceutically acceptable salt of the oligonucleotide,  
so as to thereby inhibit the accumulation of new active brain lesions, decrease or inhibit an increase in the volume of gadolinium-enhancing brain lesions and reduce the relapse rate in a human subject afflicted with the relapsing form of multiple sclerosis.

### Brief Description of Figures

[0039]

#### Figure 1:

(A, B and C) Illustrates the cumulative number of new active lesions measured by the MRI in the brain of RRMS patients on weeks 4, 8 and 12, treated with OLIGONUCLEOTIDE 1 compared to placebo. (C) OLIGONUCLEOTIDE 1 reduces the number of active lesions by 54.4%, p=0.01.

#### Figure 2:

(A and B) Illustrates the cumulative number of new active lesions measured by the MRI in the brain of RRMS patients on weeks 8 and 12, treated with OLIGONUCLEOTIDE 1 compared to placebo.

#### Figure 3:

(A, B and C) Illustrates the cumulative number of gadolinium-enhancing T1 lesions measured by the MRI in the brain of RRMS patients on weeks 4, 8 and 12, treated with OLIGONUCLEOTIDE 1 or receiving placebo. (C) OLIGONUCLEOTIDE 1 reduces the cumulative number of gadolinium-enhancing T1 lesions by 66.7%, p=0.002.

#### Figure 4:

(A and B) Illustrates the cumulative number of gadolinium-enhancing T1 lesions measured by the MRI in the brain of RRMS patients on weeks 8 and 12, treated with OLIGONUCLEOTIDE 1 or receiving placebo.

#### Figure 5:

(A and B) Illustrates the cumulative number of new or newly enlarging T2 lesions measured by the MRI in the brain of RRMS patients on weeks 4, 8 and 12, treated with OLIGONUCLEOTIDE 1 or receiving placebo.

**Figure 6:**

(A and B) Illustrates the proportion of gadolinium-enhancing lesion free subjects on weeks 8 and 12 among RRMS patients treated with OLIGONUCLEOTIDE 1 compared to placebo.

**Figure 7:**

Illustrates the trend in reduction of cumulative T1-gadolinium-enhancing lesion volume in the brain of RRMS patients over time in the treatment group compared to placebo.

**Figure 8:**

Illustrates number of new active lesions over time in the treatment group compared to placebo.

**Figure 9:**

Pharmacokinetics data. Median profiles of OLIGONUCLEOTIDE 1 show no indication of accumulating peak or total plasma exposure levels from Day 1 to Week 8.

**Detailed Description of the Invention**

**[0040]** This invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:

5'-MeC<sup>Me</sup>UG AGT MeCTG TTT MeUMeC<sup>Me</sup>C A<sup>Me</sup>UMeU MeC<sup>Me</sup>U-3' (SEQ ID NO:1)

wherein

1. a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;
2. b) the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;
3. c) the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;
4. d) the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and
5. e) all cytosines (MeC) are 5-methylcytosines,

or a pharmaceutically acceptable salt of the oligonucleotide,

for use in a method of treating multiple sclerosis, said method comprising decreasing or inhibiting the accumulation of new active brain lesions, and/or decreasing or inhibiting an increase in the volume of gadolinium-enhancing brain lesions,

wherein the pharmaceutical composition is to be periodically administered to the human subject so as to thereby decrease or inhibit the accumulation of new active brain lesions, and/or decrease or inhibit an increase in the volume of gadolinium-enhancing brain lesions, in a human subject afflicted with multiple sclerosis.

**[0041]** In an embodiment, the administration inhibits progression of disability in the human

subject.

**[0042]** In another embodiment the progression of disability is reduced by 15%-70% as measured by EDSS score relative to the progression of disability in human subjects afflicted with the form of multiple sclerosis not so treated.

**[0043]** In an embodiment, the administration inhibits the accumulation of new active brain lesions in the human subject detectable by MRI.

**[0044]** In an embodiment, the number of new active brain lesions detectable by MRI is lower by 25%-80% than the number of new active brain lesions detectable by MRI in a human subject afflicted with the form of multiple sclerosis not treated with the pharmaceutical composition.

**[0045]** In an embodiment , the number of new active brain lesions detectable by MRI is lower by 50%-65% after 8 weeks of treatment than the number of new active brain lesions detectable by MRI in a human subject afflicted with multiple sclerosis not so treated with the pharmaceutical composition. In an embodiment , the periodic administration is three times per week.

**[0046]** In one embodiment, the administration inhibits an increase in the volume of gadolinium-enhancing brain lesions of the human subject detectable by MRI.

**[0047]** In a further embodiment, the administration results in a decrease in the volume of gadolinium-enhancing brain lesions of the human subject detectable by MRI.

**[0048]** In another embodiment, the volume of gadolinium-enhancing brain lesions of the human subject afflicted with the form of multiple sclerosis is 25%-80% less than the volume of gadolinium-enhancing brain lesions of a human subject afflicted with the form of multiple sclerosis not treated with the pharmaceutical composition, wherein the lesions are detectable by MRI.

**[0049]** In a further embodiment, the MRI method is selected from the group consisting of T2-weighted scanning, precontrast T1-weighted scanning, and post-gadolinium T1-weighted scanning.

**[0050]** In one embodiment, the periodic administration is twice per week.

**[0051]** In another embodiment, the periodic administration is once per week.

**[0052]** In a further embodiment, the periodic administration is once every two weeks.

**[0053]** In an additional embodiment, the periodic administration is once every three weeks.

**[0054]** In another embodiment, the periodic administration is once every four weeks.

**[0055]** In yet another embodiment, the periodic administration is once per month.

**[0056]** In a further embodiment, the periodic administration is once per two months.

**[0057]** In one embodiment of this invention, the therapeutically effective amount is 200, 400, 600, 800, 1000, 1200, 1400 or 1600 mg.

**[0058]** In an embodiment of the method, the amount effective to treat the human subject is 50-400 mg.

**[0059]** In an additional embodiment, the amount effective to treat the human subject is 200 mg.

**[0060]** In an embodiment for periodic administration once per week, the amount effective to treat the human subject is 200 mg.

**[0061]** In an embodiment for periodic administration once every two weeks, the amount effective to treat the human subject is 200 mg.

**[0062]** In an embodiment for periodic administration once every four weeks, the amount effective to treat the human subject is 400 mg.

**[0063]** In an embodiment, the average platelet count of the human subject is above 50,000 platelets per microliter of blood during the course of administration.

**[0064]** In an embodiment, the average platelet count of the human subject is above 100,000 platelets per microliter of blood during the course of administration.

**[0065]** In an embodiment, the average platelet count of the human subject is above 150,000 platelets per microliter of blood during the course of administration.

**[0066]** In a further embodiment, the administration is effective to provide a  $C_{\max}$  of the oligonucleotide in the plasma of the human subject of 10,000-11,000 ng/ml.

**[0067]** In one embodiment, the pharmaceutical composition is administered subcutaneously.

**[0068]** In another embodiment, the oligonucleotide is in the form of a sodium salt.

**[0069]** In an additional embodiment, the oligonucleotide is in the form of a potassium salt.

**[0070]** In yet another embodiment, the pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.2-7.6. In a further embodiment, the



pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.4.

**[0071]** In an embodiment, the form of multiple sclerosis is a relapsing form of multiple sclerosis.

**[0072]** In an additional embodiment, the form of multiple sclerosis is relapsing remitting multiple sclerosis.

**[0073]** In a further embodiment, the form of multiple sclerosis includes, and OLIGONUCLEOTIDE 1 treats, at least one of the following symptoms: the accumulation of new active brain lesions, the increase in volume of gadolinium-enhanced lesions, progressive disability, an increase in the relapse rate, optic neuritis, blurring of vision, diplopia, involuntary rapid eye movement, blindness, loss of balance, tremors, ataxia, vertigo, clumsiness of a limb, lack of co-ordination, weakness of one or more extremity, altered muscle tone, muscle stiffness, spasms, tingling, paraesthesia, burning sensations, muscle pains, facial pain, trigeminal neuralgia, stabbing sharp pains, burning tingling pain, slowing of speech, slurring of words, changes in rhythm of speech, dysphagia, fatigue, bladder problems (including urgency, frequency, incomplete emptying and incontinence), bowel problems (including constipation and loss of bowel control), impotence, diminished sexual arousal, loss of sensation, sensitivity to heat, loss of short term memory, loss of concentration, or loss of judgment or reasoning.

In another embodiment, the administration reduces relapse rate in the human subject.

**[0074]** This disclosure furthermore provides a method for reducing the relapse rate in a human subject afflicted with a relapsing form of multiple sclerosis, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines ( $\text{MeC}$ ) are 5-methylcytosines,

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby reduce the relapse rate in the human subject afflicted with the relapsing form of multiple sclerosis.

**[0075]** This disclosure furthermore provides a method for inhibiting the accumulation of new active brain lesions, decreasing or inhibiting an increase in the volume of gadolinium-

enhancing brain lesions, and reducing the relapse rate in a human subject afflicted with a relapsing form of multiple sclerosis, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

1. a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;
2. b) the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;
3. c) the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;
4. d) the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and
5. e) all cytosines ( $\text{MeC}$ ) are 5-methylcytosines,

or a pharmaceutically acceptable salt of the oligonucleotide, so as to thereby inhibit the accumulation of new active brain lesions, decrease or inhibit an increase in the volume of gadolinium-enhancing brain lesions and reduce the relapse rate in a human subject afflicted with the relapsing form of multiple sclerosis

**[0076]** In another embodiment of the method, the method further comprises inhibiting progression of disability in the human subject

**[0077]** In another embodiment of the method, the progression of disability is reduced by 15%-70% as measured by EDSS score relative to the progression of disability in human subjects afflicted with the form of multiple sclerosis not so treated.

**[0078]** In an embodiment of the method, the relapsing form of multiple sclerosis is relapsing remitting multiple sclerosis.

**[0079]** In another embodiment, the relapse rate is reduced by more than 30% relative to the relapse rate of patients not so treated.

**[0080]** In an embodiment of the method, the number of new active brain lesions detectable by MRI is lower by 25%-80% than the number of new active brain lesions detectable by MRI in a human subject afflicted with the form of multiple sclerosis not treated with the pharmaceutical composition.

**[0081]** In an embodiment of the method, the number of new active brain lesions detectable by MRI is lower by 50%-65% after 8 weeks of treatment than the number of new active brain lesions detectable by MRI in a human subject afflicted with multiple sclerosis not so treated with the pharmaceutical composition.

**[0082]** In another embodiment, the volume of gadolinium-enhancing brain lesions of the human subject afflicted with the form of multiple sclerosis is 25%-80% less than the volume of gadolinium-enhancing brain lesions of a human subject afflicted with the form of multiple sclerosis not treated with the pharmaceutical composition, wherein the lesions are detectable by MRI.

**[0083]** In a further embodiment, the MRI method is selected from the group consisting of T2-weighted scanning, precontrast T1-weighted scanning, and post-gadolinium T1-weighted scanning.

**[0084]** In one embodiment, the periodic administration is twice per week.

**[0085]** In another embodiment, the periodic administration is once per week.

**[0086]** In a further embodiment, the periodic administration is once every two weeks.

**[0087]** In an additional embodiment, the periodic administration is once every three weeks.

**[0088]** In another embodiment, the periodic administration is once every four weeks.

**[0089]** In yet another embodiment, the periodic administration is once per month.

**[0090]** In a further embodiment, the periodic administration is once per two months.

**[0091]** In one embodiment of this disclosure, the therapeutically effective amount is 200, 400, 600, 800, 1000, 1200, 1400 or 1600 mg.

**[0092]** In an embodiment of this disclosure, the amount effective to treat the human subject is 50-400 mg.

**[0093]** In an additional embodiment, the amount effective to treat the human subject is 200 mg.

**[0094]** In an embodiment of the method for periodic administration once per week, the amount effective to treat the human subject is 200 mg.

**[0095]** In an embodiment of the method for periodic administration once every two weeks, the amount effective to treat the human subject is 200 mg.

**[0096]** In an embodiment of the method for periodic administration once every four weeks, the amount effective to treat the human subject is 400 mg.

**[0097]** In an embodiment of the method, the average platelet count of the human subject is above 50,000 platelets per microliter of blood during the course of administration.

**[0098]** In an embodiment of the method, the average platelet count of the human subject is above 100,000 platelets per microliter of blood during the course of administration.

**[0099]** In an embodiment of the method, the average platelet count of the human subject is above 150,000 platelets per microliter of blood during the course of administration.

**[0100]** In a further embodiment of the method, the administration is effective to provide a  $C_{\max}$  of the oligonucleotide in the plasma of the human subject of 10,000-11,000 ng/ml.

**[0101]** In one embodiment of the method, the pharmaceutical composition is administered subcutaneously.

**[0102]** In another embodiment, the oligonucleotide is in the form of a sodium salt.

**[0103]** In an additional embodiment, the oligonucleotide is in the form of a potassium salt.

**[0104]** In yet another embodiment, the pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.2-7.6. In a further embodiment, the pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.4.

**[0105]** In another embodiment, the pharmaceutical composition is administered as a monotherapy.


**[0106]** In a further embodiment, the pharmaceutical composition is administered simultaneously or sequentially with at least one additional therapeutic agent.

**[0107]** In an embodiment, the additional therapeutic agent is a corticosteroid, interferon beta-la, interferon beta-1b, glatiramer acetate or natalizumab.

**[0108]** In yet another embodiment, the additional therapeutic agent is a corticosteroid.

**[0109]** In a further embodiment, the additional therapeutic agent is glatiramer acetate.

**[0110]** This disclosure further provides a method for reducing level of VLA-4 in the blood of a human subject afflicted with a form of multiple sclerosis comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified

ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines (<sup>Me</sup>C),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby reduce the level of VLA-4 in the blood of the human subject afflicted with the form of multiple sclerosis.

**[0111]** In an embodiment of the method, the level of VLA-4 in the blood of the human subject is reduced by more than 15% relative to a human subject not so treated. In an additional embodiment the level of VLA-4 in the blood of the human subject is reduced by 10%-90% relative to a human subject not so treated. The level of VLA-4 reduction in these embodiments may be for example reduction of mRNA, protein or cell surface VLA-4. Furthermore, this level of reduction may be in one or a few of the leukocyte subsets in the blood.

**[0112]** In an embodiment of this disclosure, the periodic administration is three times per week.

**[0113]** In one embodiment, the periodic administration is twice per week.

**[0114]** In another embodiment, the periodic administration is once per week.

**[0115]** In a further embodiment, the periodic administration is once every two weeks.

**[0116]** In an additional embodiment, the periodic administration is once every three weeks.

**[0117]** In yet another embodiment, the periodic administration is once per month.

**[0118]** In a further embodiment, the periodic administration is once per two months.

**[0119]** In one embodiment of the method, the therapeutically effective amount is 200, 400, 600, 800, 1000, 1200, 1400 or 1600 mg.

**[0120]** In an embodiment of the method, the amount effective to treat the human subject is 50-400 mg.

**[0121]** In an additional embodiment, the amount effective to treat the human subject is 200 mg.

**[0122]** In an embodiment of the method for periodic administration once per week, the amount effective to treat the human subject is 200 mg.

**[0123]** In an embodiment of the method for periodic administration once every two weeks, the

amount effective to treat the human subject is 200 mg.

**[0124]** In an embodiment of the method for periodic administration once every four weeks, the amount effective to treat the human subject is 400 mg.

**[0125]** In an embodiment of the method, the average platelet count of the human subject is above 50,000 platelets per microliter of blood during the course of administration.

**[0126]** In an embodiment of the method, the average platelet count of the human subject is above 100,000 platelets per microliter of blood during the course of administration.

**[0127]** In an embodiment of the method, the average platelet count of the human subject is above 150,000 platelets per microliter of blood during the course of administration.

**[0128]** In a further embodiment of the method, the administration is effective to provide a  $C_{\max}$  of the oligonucleotide in the plasma of the human subject of 10,000-11,000 ng/ml.

**[0129]** In one embodiment of the method, the pharmaceutical composition is administered subcutaneously.

**[0130]** In another embodiment, the oligonucleotide is in the form of a sodium salt.

**[0131]** In an additional embodiment, the oligonucleotide is in the form of a potassium salt.

**[0132]** In yet another embodiment, the pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.2-7.6. In a further embodiment, the pharmaceutical carrier is WFI (water for injection) and the pharmaceutical composition is adjusted to pH 7.4.

**[0133]** This disclosure also provides a method for inhibiting the accumulation of new active brain lesions in a human subject afflicted with a form of multiple sclerosis detectable by MRI, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines (<sup>Me</sup>C),  
 or a pharmaceutically acceptable salt of the oligonucleotide,  
 so as to thereby inhibit the accumulation of new active brain lesions in the human subject  
 detectable by MRI.

**[0134]** This disclosure additionally provides a method for inhibiting an increase in the volume of gadolinium-enhancing brain lesions of a human subject afflicted with a form of multiple sclerosis detectable by MRI, comprising periodically administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines (<sup>Me</sup>C),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby inhibit an increase in the volume of gadolinium-enhancing brain lesions detectable by MRI image.

**[0135]** This disclosure also provides a method for inhibiting progression of disability in a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to a human subject afflicted with multiple sclerosis a pharmaceutical composition comprising a pharmaceutically acceptable carrier and therapeutically effective amount of an oligonucleotide having the structure:



wherein

each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester;

the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides;

the nucleotides at the positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides;

the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and

all cytosines are 5-methylcytosines (<sup>Me</sup>C),

or a pharmaceutically acceptable salt of the oligonucleotide,

so as to thereby inhibit progression of disability in the human subject.

**[0136]** As used herein, an "additional therapeutic agent" is any agent useful for treating

multiple sclerosis other than OLIGONUCLEOTIDE 1.

**[0137]** Within any range listed in this document, all integers, and tenths, including integer percentages for percentages, are contemplated as embodiments of this invention. For example, the invention provides that the amount effective to treat the human subject may be 50-400 mg; by this recitation the invention contemplates and discloses all tenths and integer mg amounts such as 51.1, 51.2 ... 399.8, 399.9; 51, 52 ... 398, 399 mg as embodiments of this invention. Similarly, by another example, the invention provides that the number of new active brain lesions detectable by MRI image is lower by 25-80% than the number of new active brain lesions detectable by MRI image in a human subject afflicted with multiple sclerosis not treated with the pharmaceutical composition; by this recitation the invention contemplates and discloses all integer % amounts such as 26%, 27%, 28% ... 78% and 79% as embodiments of this invention. Analogously for every range disclosed in this application.

**[0138]** A pharmaceutically acceptable salt as used herein refers to any salt form of the oligonucleotide 3-9-8 MOE gap-mer disclosed herein which is appropriate to administer to a human subject. In particular, a potassium salt or a sodium salt as exemplified herein can be used.

## **Definitions**

### **Kurtzke Expanded Disability Status Scale (EDSS):**

**[0139]** The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. The EDSS replaced the previous Disability Status Scales which used to bunch people with MS in the lower brackets. The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual & cerebral (according to [www.mult-sclerosis.org/expandeddisabilitystatusscale](http://www.mult-sclerosis.org/expandeddisabilitystatusscale)) .

### **Multiple Sclerosis Functional Composite (MSFC):**

**[0140]** Multiple Sclerosis Functional Composite (MSFC) is a three-part, standardized, quantitative, assessment instrument for use in clinical studies, particularly clinical trials, of MS (23). The MSFC was designed to fulfill three criteria: multidimensional to reflect the varied clinical expression of MS across patients and over time, the dimensions should change relatively independently over time, and one component should be a measure of cognitive function. The three components of the MSFC measure leg function/ambulation, arm/hand function, and cognitive function. MSFC measures disability in MS patients; and used in



evaluating the efficacy of experimental or new treatment regimens. MSFC consists of various elements designed to measure arm, leg, and cognitive disability and includes a timed 25-foot walk to measure leg mobility, a nine-hole peg test to measure arm function, and a paced auditory serial addition test to measure cognitive function. (according to: [www.nationalmssociety.org/searchresults/index.aspx?pageindex=0&pagesize=20&keywords=msfc](http://www.nationalmssociety.org/searchresults/index.aspx?pageindex=0&pagesize=20&keywords=msfc)).

### **Image Contrast on MRI:**

**[0141]** Time constants are involved in relaxation processes that establish equilibrium following radio frequency excitation. As the high-energy nuclei relax and realign they emit energy at rates which are recorded to provide information about the material they are in. The realignment of nuclear spins with the magnetic field is termed *longitudinal relaxation* and the time required for a certain percentage of the tissue's nuclei to realign is termed "Time 1" or T1 (Spin-lattice relaxation time), which is typically about 1 second at 1.5 tesla main field strength. T2-weighted imaging relies upon local dephasing of spins following the application of the transverse energy pulse; the *transverse* relaxation time is termed "Time 2" or T2 (spin-spin relaxation time), typically < 100 ms for tissue at 1.5 tesla main field strength.

**[0142]** Image contrast is created by using a selection of image acquisition parameters that weights signal by T1 or T2. In the brain, T1-weighting causes the nerve connections of white matter to appear white, and the congregations of neurons of gray matter to appear gray, while cerebrospinal fluid appears dark. The contrast of "white matter," "gray matter" and "cerebrospinal fluid" is reversed using T2 imaging.

**[0143]** As used herein, the term MRI refers to conventional or non-conventional MRI.

### **Gd-enhancing Lesions:**

**[0144]** The term "Gd-enhancing lesions" refers to lesions that result from a breakdown of the blood brain barrier, which appear in contrast studies using gadolinium contrast agents. Gadolinium enhancement provides information as to the age of a lesion, as Gd-enhancing lesions typically occur within a six week period of lesion formation.

### **T1-weighted MRI Image:**

**[0145]** The term "T1-weighted MRI image" refers to an MR-image that emphasizes T1 contrast by which lesions may be visualized. Abnormal areas in a T1-MRI weighted image are "hypointense" and appear as dark spots. These spots are generally older lesions.

**T2-weighted MRI Image:**

[0146] The term "T2-weighted MRI image" refers to an MR-image that emphasizes T2 contrast by which lesions may be visualized. T2 lesions represent new inflammatory activity. T2 hyperintensity reflect a range of pathological changes from acute inflammation to irreversible axonal loss.

**Relapses:**

[0147] Relapses are characterized by the occurrence of neurological dysfunction symptoms, appearing after a 30-day period of stability or improvement and lasting for more than 24 hours (no infection, no fever). The number of relapses are analyzed using a logistic regression model controlling for treatment and age.

[0148] "Relapse Rate" is the number of confirmed relapses per unit time. "Annualized relapse rate" is the mean value of the number of confirmed relapses per each patient multiplied by 365 and divided by the number of days on study drug per each patient.

**Progression of Disability:**

[0149] Progression of disability is assessed by means of valid, sensitive and reliable scales such as EDSS and MSFC. Progression of disability is measured as the achievement of a specified degree of disability or of a sustained worsening of relevant magnitude (1 point when EDSS scores  $\leq 5.5$ ; 0.5 points if baseline score is  $>5.5$ ). Alternatively, it can be measured as the time to reach progression or the proportion of individuals who have shown progression at pre-specified time. As a supportive parameter, disability can also be expressed by summary measures obtained from serial measures at scheduled visits, indicating the degree of disability experienced by the patient during a period of time, disregarding whether it is in relation to relapses or not.

**OLIGONUCLEOTIDE 1:**

[0150] OLIGONUCLEOTIDE 1 is a second generation phosphorothioate backbone 2'-MOE-modified chimeric oligonucleotide gap-mer designed to hybridize to the 3'-untranslated region of human Very Late Activation Antigen 4 mRNA (VLA-4 mRNA), also known as CD49d mRNA, which codes for the alpha-4 subunit of VLA-4. VLA-4 is also known as alpha-4 integrin (alpha4 beta1). OLIGONUCLEOTIDE 1 selectively inhibits VLA-4 expression in both primary human cells and in several human cell lines by hybridizing to mRNA encoding CD49, which is the  $\alpha 4$

subunit of VLA-4.

**[0151]** OLIGONUCLEOTIDE 1 is the 19-sodium salt of a 3'→-5' phosphorothioate oligonucleotide 20-mer also referred as a 3-9-8 MOE gap-mer having a molecular weight of 7230 Daltons, in which the nucleotides at positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides (2'-O-(2-methoxyethyl ribose); the nucleotides at positions 4 to 12 from the 5' end are 2'-deoxyribonucleosides of which all cytosines are 5-methylcytosines; the nucleotides at positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides.

**[0152]** The sequence of OLIGONUCLEOTIDE 1 (SEQ ID:1) is:

5'-MeC<sup>Me</sup>UG AGT MeCTG TTT MeUMeC<sup>Me</sup>C A<sup>Me</sup>UMeU MeC<sup>Me</sup>U-3'.

**[0153]** The empirical formula of OLIGONUCLEOTIDE 1 is: C<sub>233</sub>H<sub>327</sub>N<sub>60</sub>O<sub>129</sub>P<sub>19</sub>S<sub>19</sub>Na<sub>19</sub>.

**[0154]** OLIGONUCLEOTIDE 1 may be synthesized by a multi-step process that may be divided into two distinct operations: solid-phase synthesis and downstream processing. In the first operation, the nucleotide sequence of OLIGONUCLEOTIDE 1 is assembled through a computer-controlled solid-phase synthesizer. Subsequent downstream processing includes deprotection steps, preparative reversed-phase (RP) chromatographic purification, isolation and drying to yield OLIGONUCLEOTIDE 1 drug substance. The chemical synthesis of OLIGONUCLEOTIDE 1 utilizes phosphoramidite coupling chemistry followed by oxidative sulfurization and involves sequential coupling of activated monomers to an elongating oligomer, the 3'-terminus of which is covalently attached to the solid support.

#### **Detritylation (reaction a)**

**[0155]** Each cycle of the solid-phase synthesis commences with removal of the acid-labile 5'-O-4,4'-dimethoxytrityl (DMT) protecting group of the 5' terminal nucleoside of the support bound oligonucleotide. This is accomplished by treatment with an acid solution (for example dichloroacetic acid (DCA) in toluene). Following detritylation, excess reagent is removed from the support by washing with acetonitrile in preparation for the next reaction.

#### **Coupling (reaction b)**

**[0156]** Chain elongation is achieved by reaction of the 5'-hydroxyl group of the support-bound oligonucleotide with a solution of the phosphoramidite corresponding to that particular base position (e.g. for B<sub>2</sub>: MOE-MeC amidite) in the presence of an activator (for example, 1H-tetrazole). This results in the formation of a phosphite triester linkage between the incoming nucleotide synthon and the support-bound oligonucleotide chain. After the coupling reaction excess reagent is removed from the support by washing with acetonitrile in preparation for the

next reaction.

#### **Sulfurization (reaction c)**

**[0157]** The newly formed phosphite triester linkage is converted to the corresponding (O,O,O)-trialkyl phosphorothioate triester by treatment with a solution of a sulfur transfer reagent (for example, phenylacetyl disulfide). Following sulfurization, excess reagent is removed from the support by washing with acetonitrile in preparation for the next reaction.

#### **Capping (reaction d)**

**[0158]** A small proportion of the 5'-hydroxy groups available in any given cycle fail to extend. Coupling of these groups in any of the subsequent cycles would result in formation of process-related impurities ('DMT-on (n-1)-mers') which are difficult to separate from the desired product. To prevent formation of these impurities and to facilitate purification, a 'capping reagent' (for example acetic anhydride and *N*-methylimidazole/acetonitrile/pyridine) is introduced into the reactor vessel to give capped sequences. The resulting failure sequences ('DMT-off shortmers') are separated from the desired product by reversed phase HPLC purification. After the capping reaction excess reagent is removed from the support by washing with acetonitrile in preparation of the next reaction.

**[0159]** Reiteration of this basic four-step cycle using the appropriate protected nucleoside phosphoramidite allows assembly of the entire protected OLIGONUCLEOTIDE 1 sequence.

#### **Backbone Deprotection (reaction e)**

**[0160]** Following completion of the assembly portion of the process the cyanoethyl groups protecting the (O,O,O)-trialkyl phosphorothioate triester internucleotide linkages are removed by treatment with a solution of triethylamine (TEA) in acetonitrile. The reagent and acrylonitrile generated during this step are removed by washing the column with acetonitrile.

#### **Cleavage from Support and Base Deprotection (reaction f)**

**[0161]** Deprotection of the exocyclic amino groups and cleavage of the crude product from the support is achieved by incubation with aqueous ammonium hydroxide (reaction f). Purification of the crude, 5'-O-DMT-protected product is accomplished by reversed-phase high pressure liquid chromatography (RP-HPLC). The RP-HPLC step removes DMT-off failure sequences. The elution profile is monitored by UV absorption spectroscopy. Fractions containing DMT-on OLIGONUCLEOTIDE 1 product are collected and analyzed.

**Acidic Deprotection (reaction g)**

**[0162]** RP-HPLC fractions containing 5'-O-DMT-protected OLIGONUCLEOTIDE 1 are pooled and transferred to a precipitation tank. The products obtained from the purification of several syntheses are combined at this stage of the process. Purified DMT-on OLIGONUCLEOTIDE 1 is treated with acid (for example, acetic acid) to remove the DMT group attached to the 5' terminus. After acid exposure for the prescribed time and neutralization, OLIGONUCLEOTIDE 1 drug substance is isolated and dried.

**[0163]** Following the final acidic deprotection step (*reaction g*), the solution is neutralized by addition of aqueous sodium hydroxide and OLIGONUCLEOTIDE 1 drug substance is precipitated from solution by adding ethanol. The precipitated material is allowed to settle at the bottom of the reaction vessel and the ethanolic supernatant decanted. The precipitated material is redissolved in purified water and the solution pH adjusted to between pH 7.2 and 7.3. The precipitation step is repeated. The precipitated material is dissolved in water and the solution filtered through a 0.45 micron filter and transferred into disposable polypropylene trays that are then loaded into a lyophilizer. The solution is cooled to -50°C. Primary drying is carried out at 25°C for 37 h. The temperature is increased to 30°C and a secondary drying step performed for 5.5 h. Following completion of the lyophilization process, the drug substance is transferred to high density polyethylene bottles and stored at -20°C.

**Forms of Multiple Sclerosis:**

**[0164]** There are five distinct disease stages and/or types of MS:

1. 1) benign multiple sclerosis;
2. 2) relapsing-remitting multiple sclerosis (RRMS);
3. 3) secondary progressive multiple sclerosis (SPMS);
4. 4) progressive relapsing multiple sclerosis (PRMS; and
5. 5) primary progressive multiple sclerosis (PPMS)

**[0165]** Benign multiple sclerosis is a retrospective diagnosis which is characterized by 1-2 exacerbations with complete recovery, no lasting disability and no disease progression for 10-15 years after the initial onset. Benign multiple sclerosis may, however, progress into other forms of multiple sclerosis.

**[0166]** Patients suffering from RRMS experience sporadic exacerbations or relapses, as well as periods of , remission. Lesions and evidence of axonal loss may or may not be visible on MRI for patients with RRMS.

**[0167]** SPMS may evolve from RRMS. Patients afflicted with SPMS have relapses, a diminishing degree of recovery during remissions, less frequent remissions and more pronounced neurological deficits than RRMS patients. Enlarged ventricles, which are markers for atrophy of the corpus callosum, midline center and spinal cord, are visible on MRI of patients with SPMS.

**[0168]** PPMS is characterized by a steady progression of increasing neurological deficits without distinct attacks or remissions. Cerebral lesions, diffuse spinal cord damage and evidence of axonal loss are evident on the MRI of patients with PPMS. PPMS has periods of acute exacerbations while proceeding along a course of increasing neurological deficits without remissions. Lesions are evident on MRI of patients suffering from PRMS (5) .

**[0169]** A clinically isolated syndrome (CIS) is a single monosymptomatic attack compatible with MS, such as optic neuritis, brain stem symptoms, and partial myelitis. Patients with CIS that experience a second clinical attack are generally considered to have clinically definite multiple sclerosis (CDMS). Over 80 percent of patients with a CIS and MRI lesions go on to develop MS, while approximately 20 percent have a self-limited process (24, 25).

**[0170]** Multiple sclerosis may present with optic neuritis, blurring of vision, diplopia, involuntary rapid eye movement, blindness, loss of balance, tremors, ataxia, vertigo, clumsiness of a limb, lack of co-ordination, weakness of one or more extremity, altered muscle tone, muscle stiffness, spasms, tingling, paraesthesia, burning sensations, muscle pains, facial pain, trigeminal neuralgia, stabbing sharp pains, burning tingling pain, slowing of speech, slurring of words, changes in rhythm of speech, dysphagia, fatigue, bladder problems (including urgency, frequency, incomplete emptying and incontinence), bowel problems (including constipation and loss of bowel control), impotence, diminished sexual arousal, loss of sensation, sensitivity to heat, loss of short term memory, loss of concentration, or loss of judgment or reasoning.

#### **Relapsing Form of Multiple Sclerosis:**

**[0171]** The term relapsing MS includes:

1. 1) patients with RRMS;
2. 2) patients with SPMS and superimposed relapses; and
3. 3) patients with CIS who show lesion dissemination on subsequent MRI scans according to McDonald's criteria.

**[0172]** As used herein, relapsing forms of multiple sclerosis include: Relapsing-remitting multiple sclerosis (RRMS), characterized by unpredictable acute episodes of neurological dysfunction (relapses), followed by variable recovery and periods of clinical stability;

Secondary Progressive MS (SPMS), wherein patients having RRMS develop sustained deterioration with or without relapses superimposed; and

Primary progressive-relapsing multiple sclerosis (PPRMS) or progressive-relapsing multiple sclerosis (PRMS), an uncommon form wherein patients developing a progressive deterioration from the beginning can also develop relapses later on.

**[0173]** As used herein, "course of administration" refers to the entire treatment from the first administration of the compound and continuing until any cessation of periodic administration. For example, the compound may be administered once every month for 2 months, or for 6 months, or for 12 months, or for 2 years, etc.

### **Thrombocytopenia**

**[0174]** Human blood contains approximately 150,000 to 440,000 platelets per microliter. Bleeding can occur with relatively minor trauma when the platelet count falls below about 50,000 platelets per microliter of blood. Serious risks generally do not occur until the platelet count falls below 10,000 to 20,000 platelets per microliter, where bleeding may occur without any injury (26).

**[0175]** " $C_{\max}$ " refers to the maximum or "peak" concentration of a drug observed after its administration.  $C_{\min}$  refers to the minimum or "trough" concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.

### **Examples**

**[0176]** OLIGONUCLEOTIDE 1 can be obtained by the process disclosed in US Patent no. 5,968,826, 6,242,591 and 6,258,790.

### **Example 1:**

**To evaluate the efficacy and safety of a selected treatment regimen of OLIGONUCLEOTIDE 1 using MRI in patients with Relapsing Remitting MS (RRMS) compared to placebo.**

**[0177]** A double-blind, placebo-controlled, multi-centre, randomized trial was conducted in order to prove the therapeutic concept and to determine the pharmacokinetic profile of OLIGONUCLEOTIDE 1 (VLA-4 antisense oligonucleotide) by subcutaneous injections, in 77 subjects diagnosed with RRMS (see Table I).

## **Methods**

**[0178]** In order to be included in the study males and females of 18-55 years of age must have been diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS).

- Patients must have at least 9 T2 lesions or at least 4 if one is gadolinium-enhancing;
- patients must have had at least one relapse within the last 12 months;
- patients must have had no relapse four weeks prior to the beginning of the study;
- patients must have EDSS score of 0-6.0;
- patients must be able to provide written informed consent; and
- patients of childbirth potential must use reliable contraception such as surgical sterilization, oral contraceptives.

**[0179]** Exclusion criteria were as follows:

- Use of any investigational drug within two months prior to the enrolment or within four months if the investigational drug is a new chemical entity;
- patients with progressive disease;
- patients having concomitant clinically relevant findings on MRI that may interfere with outcome assessment;
- patients who have had been treated with VLA-4 antibodies, anti-CD4 antibodies, or other monoclonal antibodies;
- patients who have underwent total lymphoid irradiation at any time;
- patients who have received immune-modulating drugs within two months or immune-suppressive drugs within six months prior to the enrolment;
- patients who are HIV positive;
- patients having detectable levels of JC Virus in the blood measured by Quantitative PCR;
- patients with renal impairment having serum creatinine  $\geq 2,0$  mg/dl;
- patients having a history of clinically relevant gastrointestinal, hepatic, renal, endocrine, hematological, metabolic, neurologic (other than MS) or psychiatric disease;
- patients with infections having lymphocyte count of  $>3000/\mu\text{L}$ ;
- patients having a history of any bleedings;
- patients having a history of coagulation abnormalities;
- patients who receive concomitant acetyl salicylic acid ( $> 300$  mg/day) and phenprocoumon;
- female patients who are pregnant or breast feeding;
- patients having a history of drug or alcohol abuse;
- patients having clinically relevant abnormalities in physical findings at screening examination if interfering with the study objective; Patients who have epilepsy;
- suicidal subjects;
- patients having a history of drug allergy and/or known drug hypersensitivity; patients who



are unable to communicate or to cooperate with the Investigator due to language problem;

- patients having poor mental development or impaired cerebral function;
- patients having any medical condition which, in the judgment of the Investigator, might interfere with the objectives of the study;
- patients who have repeated participation in the study;
- patients who have contraindication for application of the study drug;
- patients who have been treated with corticosteroid within six weeks prior to the enrolment and during the study period; and
- patients must not have MRI exclusion criteria such as metal residing in the body (e.g. implants), cardiac pacemaker, valves, cochlear implants, CNS vascular clips, contrast medium allergy (Gd-DTPA).

Table I

Patient Populations			
Number of patients in analysis populations per treatment group			
	Placebo	OLIGONUCLEOTIDE 1	Total
Patients Randomized	41 (100%)	36 (100%)	77 (100%)
Safety Population (randomized and treated)	41 (100%)	36 (100%)	77 (100%)
ITT Population (valid MRI at screening at least one post-baseline MRI)	39 (95.1%)	35 (97.2%)	74 (96.1%)

Table II

Patient Baseline Characteristics			
Baseline Characteristic	Statistic	Placebo N=41	OLIGONUCLEOTIDE 1 N=36
Age (years)	Mean (SD)	38.0 (9.90)	39.6(8.78)
Gender: Female	n(%)	25 (61.0)	26 (72.2)
Male	n(%)	16 (39.0)	10 (27.8)
Duration of MS (years)	Mean (SD)	3.76 (4.14)	5.67 (6.48)
EDSS score	Mean (SD)	2.83 (1.42)	2.49 (1.17)
T1 lesion	Mean (SD)	1.1 (2.28)	1.2 (2.58)
T1 lesion volume (mm <sup>3</sup> )	Mean (SD)	121 (305.7)	151 (370.6)

### **OLIGONUCLEOTIDE 1 Administration**

**[0180]** 36 eligible patients received OLIGONUCLEOTIDE 1 in the following manner:

1. *I. Induction Cycle:*

the patients were administered with three subcutaneous 'induction' doses of OLIGONUCLEOTIDE 1 200mg/injection each, on days 1, 4, and 7.

2. *II. Maintenance Cycle:*

followed the induction cycle and comprised subcutaneous administration of 200mg/injection of OLIGONUCLEOTIDE 1 twice a week (on days 4 and 7 of the week); lasted seven weeks.

3. *III. Off-Treatment Cycle:*

followed the maintenance cycle; lasted eight weeks.

[0181] 41 eligible patients received placebo, in a similar manner as OLIGONUCLEOTIDE 1. 77 patients had completed the study.

**OLIGONUCLEOTIDE 1 Product**

[0182] The subcutaneous solution for injection contained only OLIGONUCLEOTIDE 1, in WFI (water for injection) adjusted to pH 7.4 with acid or base during compounding. The solution was clear with a light yellow color. It was packaged in Type I, flint glass vial that was stoppered with a bromobutyl rubber closure having a Teflon® coating and sealed with an aluminum flip-off overseal.

[0183] The eligible patients were randomly assigned to one of the following treatment groups:

*Treatment group A:*

<b>Active treatment (OLIGONUCLEOTIDE 1)</b>	<b>Total Dose Applied</b>
<b>Subcutaneous injection containing OLIGONUCLEOTIDE 1</b>	<b>3400 mg</b>

*Treatment group B:*

<b>Placebo treatment (Placebo)</b>	<b>Total Dose Applied</b>
<b>Subcutaneous injection containing sodium chloride and colorant only</b>	<b>none</b>

[0184] Each patient received a patient pack which consisted of 34 vials (+ 2 reserve vials) containing 100 mg OLIGONUCLEOTIDE 1 or 34 vials (+ 2 reserve vials) containing placebo solution each, and 36 syringes suitable for subcutaneous injection. A tear-off label was attached to the patient pack.

- Baseline MRI was performed on Day -7 of the study;
- week 4 MRI was performed following the 9th dose;

- week 8 MRI was performed following the 17th dose; and
- the Kurtzke Expanded-Disability-Status-Scale (EDSS) assessments were performed at visits 1, 5, 6, and 8 and also when a relapse occurred.

**Measurements*****Vital Signs:***

**[0185]** Vital signs were measured at visits 1 and 6. After the patient had been supine for 5 minutes, the systolic and diastolic blood pressure and pulse rate were measured in the supine position and always on the same arm of the patient.

***Electrocardiogram (ECG):***

**[0186]** A 12-lead ECG was performed at visits 1 and 6 after the patient had been supine for 5 minutes.

***Blood Samples:***

**[0187]** Blood samples for hematology, clinical chemistry and coagulation parameters were collected from each patient for determination of the following parameters at visit 1 and at visits 5, 6, and 8. Analysis of blood samples were carried out at local certified laboratories. Complement fragment Bb were analyzed at Bioscientia in Ingelheim.

- Hematology:  
Erythrocytes, leucocytes, neutrophils, platelets, hematocrit, hemoglobin, WBC (total), lymphocytes, monocytes.
- Clinical Chemistry:  
Sodium, potassium, urea, alkaline phosphatase, glucose,  $\gamma$ -GT, SGOT, SGPT, total bilirubin, total protein, creatinine.
- Coagulation parameters:  
Partial thromboplastine time, PT, TT.
- Blood samples for CD8+ / CD4+ cells:  
Were collected at visits 2, 6, 7 and 8. CD8+ / CD4+ cell assays was carried out at the University Essen.
- Blood samples for JC virus monitoring:  
Were collected at visits 1, 5, 6, 7, and 8. JC virus monitoring by qPCR analysis of plasma

was performed on an on-going basis and buffy coat cells had been stored frozen for possible analysis at the end of trial. The assay was carried out by Bioscientia, Ingelheim.

- Blood samples for HIV screen:

Were collected at visit 1. HIV screening was carried out by Bioscientia, Ingelheim.

***Urine samples:***

**[0188]** Urine samples for JC virus monitoring were collected from each patient at visits 1, 5, 6, 7, and 8. JC virus monitoring assay was carried out by Bioscientia, Ingelheim. Urinalysis was performed at the local laboratory.

***MRI:***

**[0189]** Five MRI scans were performed per patient, to be taken for baseline setting (Day -7), at week 4 (after 9 doses), week 8 (after 17 doses), week 12, and week 16. An additional MRI scan was performed in case of relapse. MRI assessment was done by:

- T2-weighted images;
- Precontrast T1-weighted images; and
- Post-gadolinium T1-weighted images.

**[0190]** MRI scans were analyzed by the IAC (Image Analysis Centre, VU Medical Centre, Amsterdam, The Netherlands) by an experienced reader blinded to treatment allocation.

**[0191]** Prior to initiation, each centre had asked to send a dummy scan to assess image quality and shipment procedures, and to evaluate the accessibility of the electronic data carrier. This was used to fine-tune the exact MRI sequences, which were vendor-specific. Only upon final approval of the dummy scan were the sites allowed to start scanning patients, with no deviations from the final scan-protocol for that particular site being allowed. Once patients had been enrolled, for each scan performed, the quality was assessed at the IAC and was reported to the contributing site, as part of an ongoing Quality Assurance procedure. Once the data had arrived at the IAC they were logged, copied and stored. Both sites and monitors were duly informed by fax about acceptance of scans. Lesions were marked on the hard copies by a radiologist blinded to full patient identification and treatment allocation.

***MRI Image Acquisition:***

**[0192]** The patient's position had been standardized by putting the patient's head into the head-coil in a well-defined fashion (e.g. nasal bridge at the centre). Rotation in the coronal plane was minimized by centering a horizontal light beam at the centre of the coil as well as across the orbital ridge. The head of the patient had been supported within the head-coil with foam cushions in order to minimize patient motion. Rotation in the horizontal plane had been minimized by centering a vertical light beam on the nose. A long IV line connected to a drip infusion with saline had been inserted prior to moving the patient into the scanner so that gadolinium could be injected during the session without moving the table (thus avoiding movement of the patients head between sequences).

**[0193]** All MR sequences were performed using 3 mm thick slices, with a 25 cm field of view (FOV), and a 256 x 256 square matrix to produce roughly 1 by 1 mm pixels. The actual scanning started with sagittal T1-weighted spin-echo (SE) localizer images. All transaxial images were planned from the mid-sagittal image, using 2 x 23 interleaved sections with a thickness of 3 mm using a 3 mm (100%) gap. This resulted in 46 consecutive slices with a Z-range of 13.8 cm, thus covering the head from vertex to foramen magnum; the middle slice of the upper series was aligned with the inferior border of the splenium of the corpus callosum.

**[0194]** A rectangular (e.g. 3/4 or 75%) FOV was used. It allowed a proportional reduction in the number of phase encoding steps (e.g. 192 instead of 256), as long as 1 x 1 mm square pixels were obtained without unfolding artifacts (right to left phase encoding for the transaxial images). Techniques such as "half-Fourier transform", "reduced scan-percentage" (Philips Healthcare; Best, The Netherlands) or "1/2 NEX" (General Electric Healthcare; Tirat Hacarmel, Israel) were not employed, as they substantially reduce the signal-to-noise ratio.

**[0195]** The first transaxial sequence (following the pilot scans), was a pre-contrast T1-weighted conventional spin-echo (SE) [TR 400-700ms/TE 5-25ms/2 excitations]. Afterwards, gadolinium-DTPA was administered at a standard dose of 0.1 mmol/kg, via the long IV line. The second transaxial series was a dual echo SE [2000-3000ms/TE1: 15-40ms, TE2: 60-100ms/1 excitation]. When a turbo- or fast- SE was used the turbo-factor was limited (e.g. 5-6). The third and final transaxial sequence was a post-contrast T1-weighted conventional SE [400-700ms/5-25ms/2 excitations].

#### ***Pharmacokinetics:***

#### **[0196]**

- Oligonucleotide 1:

Blood samples (7 ml) were obtained on visits 2, 5, 6, and 8 for evaluating oligonucleotide 1 plasma levels. On visits 2, 5, and 6 this was performed prior to and 1, 2, 3, 4, and 6 hours after injection of OLIGONUCLEOTIDE 1/Placebo. On visit 8 a single sample was obtained. The blood samples were centrifuged for 10 min at 1,600 g and at a temperature of 4°C 10 min after drawing. The supernatant was transferred to labeled

polypropylene tubes (2 tubes per sample) by pipetting and is further transferred to a deep-freezer for storing at a temperature of -20°C (tolerance +5°C) or lower.

- VLA-4 Measurements:

Blood samples were obtained on visits on visits 2, 6, 7 and 8 for evaluating VLA-4 levels. 36ml whole blood was needed for VLA-4 assay on lymphocytes.

- CD8+ / CD4+ Measurements:

For evaluation of CD8+ / CD4+ cell count blood samples were assayed at visits 2, 6, 7 and 8 using the 36ml blood samples obtained for VLA-4 assay.

## **Results**

### **Primary Outcome Measure**

**[0197]** Patients that had been receiving 200mg OLIGONUCLEOTIDE 1 twice per week, by a subcutaneous route of administration during the study period, had showed a significant 54.4% reduction ( $p=0.01$ ) in the cumulative number of new active lesions in the brain, including all lesions measured at weeks 4, 8 and 12 by the MRI, compared to patients that had been receiving placebo (Fig.1). Moreover, patients that had been treated with OLIGONUCLEOTIDE 1, had showed 62% reduction ( $p=0.0089$ ) in the cumulative number of new active lesions in the brain, measured at weeks 8 and 12 by the MRI, compared to the placebo group (Fig. 2) In addition, patients that had been treated with OLIGONUCLEOTIDE 1, had further showed 65% reduction ( $p=0.0053$ ) and 74% reduction ( $p=0.0026$ ) in the cumulative number of gadolinium-enhancing T1 lesions in the brain, measured at weeks 4, 8 and 12 or at weeks 8 and 12 by the MRI, compared to patients that had been receiving placebo respectively (Fig. 3-4). The cumulative number of new or newly enlarging T2 lesions in the brain measured by the MRI on weeks 4, 8 and 12 had been also reduced by the treatment with OLIGONUCLEOTIDE 1 (Fig. 5). Treatment with OLIGONUCLEOTIDE 1 had lead to 32% ( $p=0.0248$ ) increase in the number of gadolinium-enhancing lesion-free subjects, measured at weeks 8 and 12 (Fig.6) The maximal effect of OLIGONUCLEOTIDE 1 administration had been observed during the off-treatment cycle, at week 12 (Fig.8). This finding points out high stability of OLIGONUCLEOTIDE 1 and thus further supports administration of less frequent dosing and/or lower doses of OLIGONUCLEOTIDE 1.

### **Conclusions**

**[0198]** OLIGONUCLEOTIDE 1, in a placebo controlled, double-blind trial, was shown to be effective in preventing accumulation of new lesions detectable by MRI in the brain thereby slowing the progression of RRMS. This agent is a first example of an antisense oligonucleotide

which has been proven to be effective and safe in the treatment of MS.

### **Secondary Outcome Measure**

**[0199]** The secondary endpoint of the study shows a cumulative decrease in the volume of gadolinium-enhancing lesions measured by MRI (to include all lesions from weeks 4, 8, and 12), corrected to the volume of gadolinium-enhancing lesions at the baseline, in the brain of patients that had been treated with 200mg OLIGONUCLEOTIDE 1 twice per week by a subcutaneous route of administration by 84% compared to placebo group at week 12 (Fig.7).

### **Additional Measures**

#### ***Thrombocytopenia***

**[0200]** Thrombocytopenia was one of the main safety concerns. This phenomenon was observed with first generation anti-sense oligonucleotides. During the study, decrease in platelet count was observed in all patients treated with oligonucleotide 1. 12 patients (33%) had a decrease below 150,000 anytime during the treatment; 6 patients (17%) had a clinically meaningful decrease below 100,000; 2 patients had been withdrawn from study. None of the patients had bleeding episodes or any other thrombocytopenia-related clinical symptoms. All subjects displayed recovery when off drug, indicating that the effect was rapidly reversible. Changing treatment regimen to less frequent dosing is contemplated to resolve this problem while maintaining the therapeutic benefits.

#### ***Pharmacokinetic Data***

**[0201]** Median profiles of OLIGONUCLEOTIDE 1 show no indication of accumulating peak or total plasma exposure levels from Day 1 to Week 8 (Fig.9 and Table III).

**[0202]** The increase in  $C_{min}$  concentrations during the treatment phase suggests that OLIGONUCLEOTIDE 1 accumulates in tissue with multiple dose administrations. The decrease in  $C_{min}$  concentrations during the follow-up phase suggests that the  $t_{1/2}$  elimination is approximately 3 weeks.

Table III.

<b>PK Parameters of OLIGONUCLEOTIDE 1</b>	
$C_{max}$	10157 - 10895 ng/mL (mean)
$T_{max}$	3 hrs (median)

PK Parameters of OLIGONUCLEOTIDE 1	
AUC <sub>last</sub>	46587 - 48521 h·ng/mL (mean)

**Example 2:**

**[0203]** Another clinical study is performed following substantially Example 1 except the administration of OLIGONUCLEOTIDE 1 is modified to the following three groups:

1. 1) 200 mg per week;
2. 2) 200 mg every 2 weeks; and
3. 3) 400 mg every 4 weeks.

**[0204]** In this clinical trial similar effects to that of Example 1 are obtained with respect to cumulative number of new active lesions and the volume of gadolinium-enhancing lesions. In addition, a reduction in relapse rate and inhibition in the progression of disability are also observed. Furthermore, using the three types of administration, thrombocytopenia is limited and no patients are withdrawn from the trial due to a platelet count below 50,000 per microliter of blood. Most patients have a platelet count above 100,000 or 150,000 platelets per microliter of blood.

**References:****[0205]**

1. 1. McDonald WI, Compston A, Edan G et al., "Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis", Ann Neurol 2001;50:121-127
2. 2. CPMP - Committee for Proprietary Medicinal Products. "Note for Guidance on Good Clinical Practice." London, 1997, January; CPMP/ICH/135/95:1-58.
3. 3. CPMP - Committee for Proprietary Medicinal Products. "Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis." London, 1999, July 28; CPMP/EWP/561/98:1-10.
4. 4. Medizinfo, Multiple Sklerose. Epidemiologie. Available from: URL: [www.medizinfo.de/kopfundseele/multiplesklerose/msept.htm](http://www.medizinfo.de/kopfundseele/multiplesklerose/msept.htm)
5. 5. Johnson D, Hafler DA, Fallis RJ, Lees MB, Brady RO, Quarles RH, Weiner HL., "Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis.", J Neuroimmunol. 1986 Nov;13 (1):99-108.
6. 6. Chou YK, Bourdette DN, Offner H, Whitham R, Wang RY, Hashim GA, Vandenbark AA., "Frequency of T cells specific for myelin basic protein and myelin proteolipid protein



- in blood and cerebrospinal fluid in multiple sclerosis.", *J Neuroimmunol.* 1992 May; 38(1-2):105-13.
7. 7. de Rosbo NK, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A., "Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.", *J Clin Invest.* 1993 Dec; 92(6):2602-8.
  8. 8. de Rosbo NK, Ben-Nun A., "T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein.", *J Autoimmun.* 1998 Aug; 11(4):287-99.
  9. 9. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, Ravid R., "The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis.", *Nature* 1995 Jun 29;375(6534):798-801.
  10. 10. Pelfrey CM, Tranquill LR, Vogt AB, McFarland HF., "T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls.", *Mult Scler.* 1996 Apr; 1(5):270-8.
  11. 11. Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL., "Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen." *J Neuroimmunol.*, 1999 Sep 1;99(1):36-43.
  12. 12. Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron KD, Purdie DM, McCombe PA, Good MF., "Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects.", *J Immunol.* 2000 Nov 1; 165(9):5322-31.
  13. 13. Rovira A' , Leo'n A, "MR in the diagnosis and monitoring of multiple sclerosis: An overview.", *Eur J Radiol* (2008)
  14. 14. Van Oosten BW, Lai M, Hodgkinson S, Barkhof F et al., "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomised, double-blind, placebo-controlled MR-monitored phase II trial.", *Neurology.* 1997; 49:351-357.
  15. 15. Paty DW, Hashimoto SA, Ebers GC., "Management of Multiple Sclerosis and Interpretation of Clinical Trials.", *Multiple Sclerosis / editors, Paty. DW, Ebers GC, Philadelphia, 1998:457.*
  16. 16. Kuang-Yu Jen & Alan M. Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA. ", *Stem Cells* 2000;18:307-319.
  17. 17. Helene, C. and J.J. Toulme, "Specific regulation of gene expression by antisense, sense and antigene nucleic acids.", *Biochim Biophys Acta*, 1990;1049(2):99-125.
  18. 18. Cohen, J.S., "Antisense oligodeoxynucleotides as antiviral agents.", *Antiviral Res*, 1991;16(2):121-33.
  19. 19. Calabretta, B., "Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.", *Cancer Res*, 1991;51(17):4505-10.
  20. 20. Crooke, S.T., "Progress toward oligonucleotide therapeutics: pharmacodynamic properties.", *Faseb J*, 1993;7(6):533-9.
  21. 21. Crooke, S.T., "Therapeutic applications of oligonucleotides.", *Annu Rev Pharmacol Toxicol*, 1992;32:329-76.

22. 22. Steinman, L., "Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.", Nature Reviews Drug Discovery 4, 510-518 (June 2005)
23. 23. Gary R. Cutter, Monika L. Baier, Richard A. Rudick, Diane L. Cookfair, Jill S. Fischer, John Petkau, Karl Syndulko, Brian G. Weinshenker, Jack P. Antel, Christian Confavreux, George W. Ellison, Fred Lublin, Aaron E. Miller, Stephen M. Rao, Stephen Reingold, Alan Thompson and Ernest Willoughby, "Development of a multiple sclerosis functional composite as a clinical trial outcome measure.", Brain 122:871-882, 1999.
24. 24. Brex PA et al., "A longitudinal study of abnormalities on MRI and disability from multiple sclerosis", N Engl J Med 2002 Jan 17, 346(3):158-64.
25. 25. Frohman EM et al., "The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", Neurology, 2003, Sep 9, 61(5):602-11.
26. 26. The Merck Manual of Medical Information, Second Home Edition; Blood Disorders, Bleeding and Clotting Disorders. [www.merck.com/mmhe/print/sec14/ch173/ch173d.html](http://www.merck.com/mmhe/print/sec14/ch173/ch173d.html), Last full review/revision May 2006 by Joel L. Moake, MD.
27. 27.

## **SEQUENCE LISTING**

### **[0206]**

<110> Antisense Therapeutics Ltd

<120> Methods for Treating Multiple Sclerosis Using Antisense Oligonucleotides

<130> SMK/FP7103443

<140> EP

<141> 2009-06-23

<150> EP 09798248.2

<151> 2009-06-23

<150> PCT/US2009/003760

<151> 2009-06-23

<150> US 61/132,973

<151> 2008-06-23

<160> 1

<170> PatentIn version 3.5

<210> 1

<211> 20

<212> DNA

<213> artificial

<220>

<223> Chemically synthesized

<220>

<221> modified ribonucleoside and modified cytosine

<222> (1)..(1)

<223> 2'-O-(2-methoxyethyl) ribose and 5-methylcytosine

<220>

<221> 2'-O-(2-methoxyethyl) modified ribonucleoside

<222> (2)..(3)

<223> 2'-O-(2-methoxyethyl) ribose

<220>

<221> 2'-deoxyribonucleoside

<222> (4)..(6)

<223> 2'-deoxyribonucleosides

<220>

<221> 5-methylcytosine

<222> (7)..(7)

<223> 5-methylcytosine

<220>

<221> 2'-deoxyribonucleoside

<222> (8)..(12)

<223> 2'-deoxyribonucleosides

<220>

<221> modified ribonucleoside

<222> (13)..(13)

<223> 2'-O-(2-methoxyethyl) ribose

<220>

<221> modified ribonucleoside and modified cytosine

<222> (14)..(15)

<223> 2'-O-(2-methoxyethyl) ribose and 5-methylcytosine

<220>

<221> modified ribonucleoside

<222> (16)..(18)

<223> 2'-O-(2-methoxyethyl) ribose

<220>

<221> modified ribonucleoside and modified cytosine

<222> (19)..(19)

<223> 2'-O-(2-methoxyethyl) ribose and 5-methylcytosine

<220>

<221> modified ribonucleoside

<222> (20)..(20)

<223> 2'-O-(2-methoxyethyl) ribose

<400> 1

cugagtctgt ttuccauucu 20

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description

- [US61132973A \[0001\]](#)
- [US5968826A \[0176\]](#)
- [US6242591B \[0176\]](#)
- [US6258790B \[0176\]](#)
- [EP09798248A \[0206\]](#)
- [US2009003760W \[0206\]](#)
- [US61132973B \[0206\]](#)

### Non-patent literature cited in the description

- Crohn's disease. Natalizumab United States Food and Drug Administration 20040000 [\[0020\]](#)
- **GODREY, J.** Drug Discovery Today, 2004, vol. 1, 285-91 [\[0025\]](#)
- **RAYBURN, E. R.** Drug Discover Today, 2008, vol. 13, 11-12 513-521 [\[0026\]](#)

- **COREY, D. R.** Nature Chemical biology, 2007, vol. 3, 18-11 [0027]
- **TAFECH, A.** Current Medicinal Chemistry, 2006, vol. 13, 8863-881 [0028]
- **COISNE, C.** Inflammation and allergy drug targets, 2007, vol. 6, 4210-222 [0029]
- **MYERS, K. J.** Journal of Neuroimmunology, 2005, vol. 160, 1-212-24 [0030]
- **MCDONALD WICOMPSTON AEDAN G et al.** Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis Ann Neurol, 2001, vol. 50, 121-127 [0205]
- **CPMP - Committee for Proprietary Medicinal Products** Note for Guidance on Good Clinical Practice, 1997, vol. 95, 1-58 [0205]
- **CPMP - Committee for Proprietary Medicinal Product** Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis, 1999, vol. 98, 1-10 [0205]
- **MEDIZINFO** Multiple Sklerose. Epidemiologie, [0205]
- **JOHNSON DHAFLE R DAFALLIS RJLEES MBBRADY ROQUARLES RHWEINER HL.** Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis J Neuroimmunol, 1986, vol. 13, 199-108 [0205]
- **CHOU YKBOURDETTE DNOFFNER HWHITHAM RWANG RYHASHIM GAVANDENBARK AA.** Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis J Neuroimmunol, 1992, vol. 38, 1-2105-13 [0205]
- **DE ROSBO NKMILO RLEES MBBURGER DBERNARD CCBEN-NUN A.** Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein J Clin Invest, 1993, vol. 92, 62602-8 [0205]
- **DE ROSBO NKBEN-NUN A.** T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein J Autoimmun, 1998, vol. 11, 4287-99 [0205]
- **VAN NOORT JMVAN SEHEL ACBAJRAMOVIC JJEL OUAGMIRI MPOLMAN CHLASSMANN HRAVID R.** The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis Nature, 1995, vol. 375, 6534798-801 [0205]
- **PELFREY CMTRANQUILL LRVOGT ABMCFARLAND HF.** T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls Mult Scler, 1996, vol. 1, 5270-8 [0205]
- **DIAZ-VILLOSLADA PSHIH ASHAO LGENAIN CPHAUSER SL** Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen J Neuroimmunol., 1999, vol. 99, 136-43 [0205]
- **PENDER MPCSURHES PAGREER JMMOWAT PDHENDERSON RDCAMERON KDPURDIE DMMCCOMBE PAGOOD MFSurges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects J Immunol., 2000, vol. 165, 95322-31 [0205]**
- **ROVIRA ALEO'N AMR** in the diagnosis and monitoring of multiple sclerosis: An overview Eur J Radiol, 2008, [0205]
- **VAN OOSTEN BWLAI MHODGKINSON SBARKHOF F et al.** Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomised,

double-blind, placebo-controlled MR-monitored phase II trial *Neurology*, 1997, vol. 49, 351-357 [0205]

- Management of Multiple Sclerosis and Interpretation of Clinical Trials **PATY DWHASHIMOTO SAEBERS GC**. *Multiple Sclerosis* 1998 0000457- [0205]
- **KUANG-YU JENALAN M. GEWIRTZ** Suppression of Gene Expression by Targeted Disruption of Messenger RNA *Stem Cells*, 2000, vol. 18, 307-319 [0205]
- **HELENE, C.J.J. TOULME** Specific regulation of gene expression by antisense, sense and antigen nucleic acids *Biochim Biophys Acta*, 1990, vol. 1049, 299-125 [0205]
- **COHEN, J.S.** Antisense oligodeoxynucleotides as antiviral agents *Antiviral Res*, 1991, vol. 16, 2121-33 [0205]
- **CALABRETTA, B.** Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications *Cancer Res*, 1991, vol. 51, 174505-10 [0205]
- **CROOKE, S.T.** Progress toward oligonucleotide therapeutics: pharmacodynamic properties *Faseb J*, 1993, vol. 7, 6533-9 [0205]
- **CROOKE, S.T.** Therapeutic applications of oligonucleotides *Annu Rev Pharmacol Toxicol*, 1992, vol. 32, 329-76 [0205]
- **STEINMAN, L.** Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab *Nature Reviews Drug Discovery*, 2005, vol. 4, 510-518 [0205]
- **GARY R. CUTTER MONIKA L. BAIER RICHARD A. RUDICK IANE L. COOK FAIR JILL S. FISCHER JOHN PETKAU KARL SYNDUL KOBRIAN G. WEINSHENKER JACK P. ANTEL CHRISTIAN CONFAYREUX** Development of a multiple sclerosis functional composite as a clinical trial outcome measure *Brain*, 1999, vol. 122, 871-882 [0205]
- **BREX PA et al.** A longitudinal study of abnormalities on MRI and disability from multiple sclerosis *N Engl J Med*, 2002, vol. 346, 3158-64 [0205]
- **FROHMAN EM et al.** The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology *Neurology*, 2003, vol. 61, 5602-11 [0205]
- The Merck Manual of Medical Information **JOEL L. MOAKE** Blood Disorders, Bleeding and Clotting Disorders 2006 0500 [0205]

## PATENTKRAV

1. Farmaceutisk sammensætning indeholdende et farmaceutisk acceptabelt bærestof og en terapeutisk virksom mængde af et oligonukleotid med strukturen:

5 5'-MeC<sup>Me</sup>UG AGT <sup>Me</sup>CTG TTT <sup>Me</sup>U<sup>Me</sup>C<sup>Me</sup>C A<sup>Me</sup>U<sup>Me</sup>U MeC<sup>Me</sup>U-3' (SEQ ID NO:1)

i hvilken

a) hver af de 19 internukleotidbindinger i oligonukleotidet er en *O,O*-bundet phosphorthioatdiester;

b) nukleotiderne i stillingerne 1 til 3 fra 5'-enden er 2'-*O*-(2-methoxyethyl)-  
10 modificerede ribonukleosider;

c) nukleotiderne i stillingerne 4 til 12 fra 5'-enden er 2'-deoxyribonukleosider;

d) nukleotiderne i stillingerne 13 til 20 fra 5'-enden er 2'-*O*-(2-methoxyethyl)-  
modificerede ribonukleosider; og

e) alle cytosiner (<sup>Me</sup>C) er 5-methylcytosiner,

15 eller et farmaceutisk acceptabelt salt af oligonukleotidet,

til anvendelse ved en fremgangsmåde til behandling af multipel sklerose, hvilken fremgangsmåde omfatter formindskelse eller inhibering af akkumuleringen af nye aktive hjernelæsioner, og/eller nedsættelse eller inhibering af en forøgelse i volumenet af gadolinium-forstærkende hjernelæsioner,

20 hvor den farmaceutiske sammensætning skal indgives periodisk til det menneskelige individ for derved at formindske eller inhibere akkumuleringen af nye aktive hjernelæsioner og/eller formindske eller inhibere en forøgelse i volumenet af gadolinium-forstærkende hjernelæsioner i et menneskeligt individ angrebet af multipel sklerose.

25

2. Farmaceutisk sammensætning ifølge krav 1 til anvendelse som defineret i krav 1, hvor antallet af nye aktive hjernelæsioner, der kan detekteres med MRI, er:

i) 25%-80% lavere end antallet af nye aktive hjernelæsioner, der kan detekteres med MRI i et menneskeligt individ angrebet af multipel sklerose, og som ikke har  
30 fået indgivet den farmaceutiske sammensætning, eller

ii) 50%-65% lavere efter 8 ugers behandling end antallet af nye aktive hjernelæsioner, der kan detekteres med MRI i et menneskeligt individ angrebet af multipel sklerose, og som ikke har fået indgivet den farmaceutiske sammensætning.

3. Farmaceutisk sammensætning ifølge krav 1 eller krav 2 til anvendelse som defineret i krav 1, hvor volumenet af gadolinium-forstærkende hjernelæsioner, der kan detekteres med MRI, er 25%-80% mindre end volumenet af gadolinium-forstærkende hjernelæsioner, der kan detekteres med MRI i et menneskeligt individ angrebet af multipel sklerose, og som ikke har fået indgivet den farmaceutiske sammensætning.
4. Farmaceutisk sammensætning ifølge krav 2 eller krav 3 til anvendelse som defineret i krav 1, hvor MRI-metoden er valgt fra gruppen bestående af T2-vægtet skanning, prækontrast T1-vægtet skanning og post-gadolinium T1-vægtet skanning.
5. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 4 til anvendelse som defineret i krav 1, hvor den multiple sklerose er primær progressiv multipel sklerose eller sekundær progressiv multipel sklerose.
6. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 5 til anvendelse som defineret i krav 1, yderligere omfattende inhibering af progression af invaliditet i det menneskelige individ.
7. Farmaceutisk sammensætning ifølge krav 6 til anvendelse som defineret i krav 1, hvor progressionen af invaliditet er formindsket med 15%-70% som målt ved EDSS-bedømmelse i forhold til progressionen af invaliditet hos et menneskeligt individ angrebet af formen for multipel sklerose, der ikke har fået indgivet den farmaceutiske sammensætning.
8. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 7 til anvendelse som defineret i krav 1, hvor den periodiske indgivelse finder sted:
- i) én gang pr. uge,
  - ii) to gange pr. uge,
  - iii) én gang hver anden uge,
  - iv) én gang hver tredje uge,
  - v) én gang hver fjerde uge eller



vi) én gang pr. måned.

9. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 8 til anvendelse som defineret i krav 1, hvor den mængde, der er virksom til at  
5 formindske eller inhibere akkumuleringen af nye aktive hjernelæsioner, eller formindske eller inhibere forøgelsen i volumenet af gadolinium-forstærkende hjernelæsioner, eller inhibere progression af invaliditet, er:

- i) 50-400 mg,
- ii) 200 mg,
- 10 iii) 400 mg eller
- iv) 50 mg til mindre end 400 mg.

10. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 7 til anvendelse som defineret i krav 1, hvor den mængde, der er virksom til at  
15 formindske eller inhibere akkumuleringen af nye aktive hjernelæsioner, eller formindske eller inhibere forøgelsen i volumenet af gadolinium-forstærkende hjernelæsioner, eller inhibere progression af invaliditet i det menneskelige individ, er:

- i) 200 mg én gang om ugen,
- 20 ii) 200 mg én gang hver anden uge eller
- iii) 400 mg én gang hver fjerde uge.

11. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 10 til anvendelse som defineret i krav 1, hvor den gennemsnitlige blodpladetælling i det  
25 menneskelige individ er mere end:

- i) 100.000 blodplader pr. mikroliter blod under indgivelsesforløbet eller
- ii) 150.000 blodplader pr. mikroliter blod under indgivelsesforløbet.

12. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 11 til  
30 anvendelse som defineret i krav 1, hvor indgivelsen er virksom til at tilvejebringe en  $C_{\max}$  af oligonukleotidet i plasmaet i det menneskelige individ på 10.000-11.000 ng/ml.

13. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 12 til anvendelse som defineret i krav 1, hvor den farmaceutiske sammensætning indgives subkutan.
- 5 14. Farmaceutisk sammensætning ifølge ethvert af kravene 1 til 13 til anvendelse som defineret i krav 1, hvor oligonukleotidet er i form af et natriumsalt eller et kaliumsalt, eller hvor
- i) det farmaceutiske bærestof er WFI (vand til injektionsformål), og den farmaceutiske sammensætning er indstillet på pH 7,2-7,6, eller
- 10 ii) det farmaceutiske bærestof er WFI (vand til injektionsformål), og den farmaceutiske sammensætning er indstillet på pH 7,4.
-

# DRAWINGS



**Fig. 1****A.****B.**

Fig 1.

C.





Fig.2

A.



B.





Fig.3

A.



B.




Fig. 3

C.





Fig. 4

A.



B.







Fig. 5

A.



B.





Fig. 6

A.



B.




Fig. 7




Fig. 8




Fig. 9

